Mario Strazzabosco

Mario Strazzabosco, MD, PhD, is a Professor of Medicine in the Department of Internal Medicine (Digestive Diseases) at Yale School of Medicine. He serves as Clinical Program Leader of the Liver Cancer Program at Yale Cancer Center, Co-Director of the Yale Liver Center, and Director of the Smilow Liver Cancer Program. Previously, he held leadership positions at the University of Milan, including Founding Chief of the Section of Digestive Diseases, Chair of the Department of Surgery and Translational Medicine, and Vice President of the School of Medicine.

Dr. Strazzabosco's research focuses on the pathophysiology and therapy of cholangiopathies (diseases of the biliary tree), including Cystic Fibrosis cholangiopathy, polycystic liver disease, and Alagille syndrome. His laboratory investigates the role of biliary cells in liver repair and regeneration, as well as hepatocellular carcinoma therapy. His work aims to translate basic discoveries in liver cell biology into advanced patient care.

Analysis of Dr. Strazzabosco's recent publications (2024-2025) reveals a strong focus on liver cancer diagnostics, treatment response assessment, and the molecular mechanisms underlying biliary diseases. His work spans clinical research on HCC staging systems and cost-effectiveness, molecular studies of cholangiocarcinoma metastasis, and investigations into the pathophysiology of primary sclerosing cholangitis.

• NIH funding recipient for liver disease research
• Active contributor to hepatology literature with multiple high-impact publications

As Clinical Program Leader, Dr. Strazzabosco oversees a multidisciplinary team that provides coordinated care for liver cancer patients. His clinical approach emphasizes personalized treatment that preserves liver function while addressing cancer, with collaboration across medical oncology, interventional radiology, surgical oncology, hepatology, and transplantation surgery specialties. His Hepar Lab serves as the research hub for translating basic science discoveries into clinical applications for liver disease patients.